Table IV.

Associations of Burkitt lymphoma incidence with HLA mismatch and treatment characteristics

Characteristic	BL cases	Incidence rates*	Incidence rate ratios	95% confidence Intervals
HLA mismatch score¶
0	3	4.2	0.37	0.09, 1.06
1	5	16.7	1.44	0.48, 3.53
2	10	12.0	1.04	0.47, 2.14
3	13	8.2	0.70	0.34, 1.39
4	14	8.0	0.69	0.34, 1.35
5	21	11.6	Ref.
6	6	6.6	0.57	0.21, 1.34
Missing	27	21.9	1.89	1.07, 3.38
Induction medications
Polyclonal antibody
No	92	11.9	Ref.
Yes	7	4.9	0.41	0.17, 0.82
Monoclonal antibody
No	90	10.6	Ref.
Yes	9	13.2	1.24	0.58, 2.33
IL2RA
No	91	11.5	Ref.
Yes	8	6.4	0.56	0.25, 1.08
Maintenance medications
Cyclosporine
No	46	11.2	Ref.
Yes	53	10.5	0.93	0.63, 1.39
Tacrolimus
No	62	10.7	Ref.
Yes	37	11.0	1.03	0.68, 1.53
mTOR inhibitors
No	97	11.2	Ref.
Yes	2	4.7	0.43	0.07, 1.34
Azathioprine
No	74	12.0	Ref.
Yes	25	8.3	0.69	0.43, 1.07
MMF
No	67	12.8	Ref.
Yes	32	8.2	0.64	0.41, 0.96
Corticosteroids
No	18	20.9	Ref.
Yes	81	9.8	0.47	0.29, 0.80

IL2RA= interleukin-2 receptor antagonist; mTOR= mammalian target of rapamycin; MMF=mycophenolate mofetil ;

^*Incidence per 100,000 person-years ;

^¶HLA mismatch score is the sum of mismatches at A, B, and DR loci.